[1] Ramirez-Sandoval, J. C., & Madero, M. (2018). Treatment of Hyperuricemia in Chronic Kidney Disease. Contrib Nephrol, 192, 135-146. doi:10.1159/000484288
[2] Lima, W. G., Martins-Santos, M. E., & Chaves, V. E. (2015). Uric acid as a modulator of glucose and lipid metabolism. Biochimie, 116, 17-23. doi:10.1016/j.biochi.2015.06.025
[3] Battelli, M. G., Polito, L., Bortolotti, M., & Bolognesi, A. (2016). Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme. Current Medicinal Chemistry, 23(35), 4027-4036. doi:10.2174/0929867323666160725091915
[4] Isaka, Y., Takabatake, Y., Takahashi, A., Saitoh, T., & Yoshimori, T. (2016). Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant, 31(6), 890-896. doi:10.1093/ndt/gfv024
[5] Liu, X., Zhao, X., Duan, X., Wang, X., Wang, T., Feng, S., . . . Li, G. (2021). Knockout of NGAL aggravates tubulointerstitial injury in a mouse model of diabetic nephropathy by enhancing oxidative stress and fibrosis. Exp Ther Med, 21(4), 321. doi:10.3892/etm.2021.9752
[6] Li, C., Hsieh, M. C., & Chang, S. J. (2013). Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol, 25(2), 210-216. doi:10.1097/BOR.0b013e32835d951e
[7] Becker, M. A., Schumacher, H. R., Jr., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., . . . Joseph-Ridge, N. (2005). Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med, 353(23), 2450-2461. doi:10.1056/NEJMoa050373
[8] Vargas-Santos, A. B., & Neogi, T. (2017). Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis, 70(3), 422-439. doi:10.1053/j.ajkd.2017.01.055
[9] Jordan, A., & Gresser, U. (2018). Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat. Pharmaceuticals (Basel), 11(2). doi:10.3390/ph11020051
[10] Zeng, X. X., Tang, Y., Hu, K., Zhou, X., Wang, J., Zhu, L., . . . Xu, J. (2018). Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine (Baltimore), 97(13), e0161. doi:10.1097/md.0000000000010161
[11] Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000). Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta, 1492(1), 203-206. doi:10.1016/s0167-4781(00)00067-1
[12] BonDurant, L. D., & Potthoff, M. J. (2018). Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis. Annu Rev Nutr, 38, 173-196. doi:10.1146/annurev-nutr-071816-064800
[13] Salgado, J. V., Goes, M. A., & Salgado Filho, N. (2021). FGF21 and Chronic Kidney Disease. Metabolism-Clinical And Experimental, 118, 154738. doi:10.1016/j.metabol.2021.154738
[14] Fisher, F. M., & Maratos-Flier, E. (2016). Understanding the Physiology of FGF21. Annu Rev Physiol, 78, 223-241. doi:10.1146/annurev-physiol-021115-105339
[15] Dolegowska, K., Marchelek-Mysliwiec, M., Nowosiad-Magda, M., Slawinski, M., & Dolegowska, B. (2019). FGF19 subfamily members: FGF19 and FGF21. Journal Of Physiology And Biochemistry, 75(2), 229-240. doi:10.1007/s13105-019-00675-7
[16] Kim, J. H., Lee, G. Y., Maeng, H. J., Kim, H., Bae, J. H., Kim, K. M., & Lim, S. (2021). Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model. Endocrinol Metab (Seoul), 36(1), 157-170. doi:10.3803/EnM.2020.781
[17] Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., . . . Kharitonenkov, A. (2013). LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. Plos One, 8(6), e65763. doi:10.1371/journal.pone.0065763
[18] Jiang, X., Liu, S., Wang, Y., Zhang, R., Opoku, Y. K., Xie, Y., . . . Ren, G. (2020). Fibroblast growth factor 21: a novel long-acting hypoglycemic drug for canine diabetes. Naunyn Schmiedebergs Arch Pharmacol. doi:10.1007/s00210-020-02023-9
[19] Jimenez, V., Jambrina, C., Casana, E., Sacristan, V., Muñoz, S., Darriba, S., . . . Bosch, F. (2018). FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med, 10(8). doi:10.15252/emmm.201708791
[20] Yu, D., Ye, X., Che, R., Wu, Q., Qi, J., Song, L., . . . Li, D. (2017). FGF21 exerts comparable pharmacological efficacy with Adalimumab in ameliorating collagen-induced rheumatoid arthritis by regulating systematic inflammatory response. Biomed Pharmacother, 89, 751-760. doi:10.1016/j.biopha.2017.02.059
[21] Chen, S., Chen, D., Yang, H., Wang, X., Wang, J., & Xu, C. (2020). Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis. BMC Gastroenterol, 20(1), 39. doi:10.1186/s12876-020-01189-z
[22] Pan, J., Shi, M., Li, L., Liu, J., Guo, F., Feng, Y., . . . Fu, P. (2019). Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy. Biomed Pharmacother, 109, 1802-1808. doi:10.1016/j.biopha.2018.11.022
[23] Zhang, S., Yu, D., Wang, M., Huang, T., Wu, H., Zhang, Y., . . . Li, D. (2018). FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro. Biomed Pharmacother, 103, 1516-1525. doi:10.1016/j.biopha.2018.03.100
[24] Wang, N., Li, J. Y., Li, S., Guo, X. C., Wu, T., Wang, W. F., & Li, D. S. (2018). Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages. Biomed Pharmacother, 108, 1825-1834. doi:10.1016/j.biopha.2018.09.143
[25] Nikolic-Paterson, D. J., & Atkins, R. C. (2001). The role of macrophages in glomerulonephritis. Nephrol Dial Transplant, 16 Suppl 5, 3-7. doi:10.1093/ndt/16.suppl_5.3
[26] Bellezza, I., Giambanco, I., Minelli, A., & Donato, R. (2018). Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res, 1865(5), 721-733. doi:10.1016/j.bbamcr.2018.02.010
[27] Karbowska, A., Boratynska, M., Kusztal, M., & Klinger, M. (2009). Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transplant Proc, 41(8), 3052-3055. doi:10.1016/j.transproceed.2009.07.080
[28] Kimura, Y., Yanagida, T., Onda, A., Tsukui, D., Hosoyamada, M., & Kono, H. (2020). Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. Arterioscler Thromb Vasc Biol, 40(3), 570-582. doi:10.1161/atvbaha.119.313224
[29] Watanabe, S., Alexander, M., Misharin, A. V., & Budinger, G. R. S. (2019). The role of macrophages in the resolution of inflammation. J Clin Invest, 129(7), 2619-2628. doi:10.1172/jci124615
[30] Hotchkiss, K. M., Reddy, G. B., Hyzy, S. L., Schwartz, Z., Boyan, B. D., & Olivares-Navarrete, R. (2016). Titanium surface characteristics, including topography and wettability, alter macrophage activation. Acta Biomater, 31, 425-434. doi:10.1016/j.actbio.2015.12.003
[31] Youm, Y. H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., . . . Dixit, V. D. (2015). The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med, 21(3), 263-269. doi:10.1038/nm.3804
[32] Johnson, R. J., Nakagawa, T., Jalal, D., Sánchez-Lozada, L. G., Kang, D. H., & Ritz, E. (2013). Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant, 28(9), 2221-2228. doi:10.1093/ndt/gft029
[33] Ricard-Blum, S., Baffet, G., & Théret, N. (2018). Molecular and tissue alterations of collagens in fibrosis. Matrix Biol, 68-69, 122-149. doi:10.1016/j.matbio.2018.02.004
[34] Meng, X. M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016). TGF-β: the master regulator of fibrosis. Nat Rev Nephrol, 12(6), 325-338. doi:10.1038/nrneph.2016.48
[35] Han, Y., Xu, X., Tang, C., Gao, P., Chen, X., Xiong, X., . . . Sun, L. (2018). Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis. Redox Biol, 16, 32-46. doi:10.1016/j.redox.2018.02.013
[36] Liu, R. M., & Gaston Pravia, K. A. (2010). Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radic Biol Med, 48(1), 1-15. doi:10.1016/j.freeradbiomed.2009.09.026
[37] Abeyrathna, P., & Su, Y. (2015). The critical role of Akt in cardiovascular function. Vascul Pharmacol, 74, 38-48. doi:10.1016/j.vph.2015.05.008
[38] Lee, Y. J., Jeong, H. Y., Kim, Y. B., Lee, Y. J., Won, S. Y., Shim, J. H., . . . Lee, S. H. (2012). Reactive oxygen species and PI3K/Akt signaling play key roles in the induction of Nrf2-driven heme oxygenase-1 expression in sulforaphane-treated human mesothelioma MSTO-211H cells. Food Chem Toxicol, 50(2), 116-123. doi:10.1016/j.fct.2011.10.035
[39] Yu, Y., Bai, F., Liu, Y., Yang, Y., Yuan, Q., Zou, D., . . . Li, D. (2015). Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways. Mol Cell Biochem, 403(1-2), 287-299. doi:10.1007/s11010-015-2358-6